Recurrent Adult Soft Tissue Sarcoma Clinical Trial
Official title:
A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas
This phase II trial is studying how well sorafenib works in treating patients with metastatic, locally advanced, or recurrent sarcoma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Status | Completed |
Enrollment | 147 |
Est. completion date | March 2011 |
Est. primary completion date | March 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed sarcoma, including any of the following neoplastic subtypes: - Giant hemangioma - Angiosarcoma (including epithelioid hemangioendothelioma) - Malignant peripheral nerve sheath tumor - Leiomyosarcoma (closed to accrual as of 11/29/06) - High-grade undifferentiated pleomorphic sarcoma (i.e., malignant fibrous histiocytoma [including myxofibrosarcoma]) (closed to accrual as of 11/29/06) - Synovial sarcoma (closed to accrual as of 11/29/06) - Carcinosarcoma (closed to accrual as of 11/29/06) - Metastatic, locally advanced, or locally recurrent disease - Measurable disease, defined as = 1 unidimensionally measurable lesion = 20 mm by conventional techniques OR = 10 mm by spiral CT scan - Lesions in a previously irradiated area may be considered measurable provided there is evidence of subsequent disease progression that cannot be attributed to necrosis or bleeding - No gastrointestinal stromal tumor - No known brain metastases - Performance status - ECOG 0-2 - Absolute neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - No evidence of bleeding diathesis - Bilirubin = 1.5 mg/dL - INR = 1.5 - AST and ALT = 2.5 times upper limit of normal - Creatinine = 1.5 mg/dL - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - No uncontrolled hypertension - No history of allergic reaction to compounds of similar chemical or biologic composition to sorafenib - No known HIV positivity - No active or ongoing infection - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No psychiatric illness or social situation that would preclude study compliance - No swallowing dysfunction that would preclude the swallowing of tablets - Other malignancies allowed provided sarcoma is the primary disease requiring treatment - No other uncontrolled illness - No more than 1 prior chemotherapy regimen for recurrent or metastatic disease (= 3 regimens for angiosarcoma or malignant peripheral nerve sheath tumor) - Adjuvant chemotherapy completed > 1 year prior to study entry is not considered a line of prior treatment - More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) - At least 3 weeks since prior radiotherapy - Recovered from prior antitumor therapy - Alopecia allowed - No prior sorafenib - No prior small molecule inhibitors of MAPK signaling intermediates - No concurrent therapeutic anticoagulation - Prophylactic anticoagulation (i.e., low-dose warfarin) of venous or arterial devices allowed provided requirements for PT, INR, or PTT requirements are met - No other concurrent investigational agents - No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital) - No concurrent rifampin or Hypericum perforatum (St. John's wort) |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST | A 5% response rate is considered not promising, a 20% response rate is considered promising. For each stratum, the response rate will be estimated and a confidence interval will be constructed. | Up to 4 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01206140 -
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT01222715 -
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
|
Phase 2 | |
Completed |
NCT01553539 -
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00098579 -
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
Completed |
NCT01462630 -
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
|
Phase 2 | |
Completed |
NCT01016015 -
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
|
Phase 2 | |
Completed |
NCT00084630 -
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
|
Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT01782313 -
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
|
Phase 2 | |
Completed |
NCT02357810 -
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
|
Phase 2 | |
Terminated |
NCT00233948 -
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
Completed |
NCT00919269 -
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
|
||
Completed |
NCT01532687 -
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT01154452 -
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT00937495 -
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00720174 -
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT00330421 -
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
|
Phase 2 | |
Completed |
NCT00087074 -
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
|
Phase 2 |